[go: up one dir, main page]

MX2009005935A - Compuestos biciclicos y su uso como anti-diabeticos. - Google Patents

Compuestos biciclicos y su uso como anti-diabeticos.

Info

Publication number
MX2009005935A
MX2009005935A MX2009005935A MX2009005935A MX2009005935A MX 2009005935 A MX2009005935 A MX 2009005935A MX 2009005935 A MX2009005935 A MX 2009005935A MX 2009005935 A MX2009005935 A MX 2009005935A MX 2009005935 A MX2009005935 A MX 2009005935A
Authority
MX
Mexico
Prior art keywords
chemical compounds
compounds
useful
treatment
making
Prior art date
Application number
MX2009005935A
Other languages
English (en)
Inventor
Andrew J Carpenter
Jing Fang
Tangjun
Gregory Peckham
Christopher R Conlee
Kien S Du
Subby Reddy Katamreddy
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of MX2009005935A publication Critical patent/MX2009005935A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F2/00—Processes of polymerisation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/24—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by sulfur atoms to which a second hetero atom is attached
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F2400/00—Characteristics for processes of polymerization
    • C08F2400/02—Control or adjustment of polymerization parameters

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Polymers & Plastics (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)
  • Treatments For Attaching Organic Compounds To Fibrous Goods (AREA)

Abstract

La presente invención se refiere a compuestos novedosos que son útiles en el tratamiento de los trastornos metabólicos, en particular diabetes mellitus tipo II y trastornos relacionados, y también a los métodos para la elaboración y uso de estos compuestos.
MX2009005935A 2006-12-06 2007-12-05 Compuestos biciclicos y su uso como anti-diabeticos. MX2009005935A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US86878906P 2006-12-06 2006-12-06
PCT/US2007/086434 WO2008070692A2 (en) 2006-12-06 2007-12-05 Bicyclic compounds and use as antidiabetics

Publications (1)

Publication Number Publication Date
MX2009005935A true MX2009005935A (es) 2009-06-30

Family

ID=39410039

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009005935A MX2009005935A (es) 2006-12-06 2007-12-05 Compuestos biciclicos y su uso como anti-diabeticos.

Country Status (23)

Country Link
US (2) US8101634B2 (es)
EP (2) EP2094683B1 (es)
JP (1) JP5330260B2 (es)
KR (1) KR20090097184A (es)
CN (1) CN101657471B (es)
AT (1) ATE528300T1 (es)
AU (1) AU2007329395B2 (es)
BR (1) BRPI0719941A2 (es)
CA (1) CA2671749C (es)
CO (1) CO6210752A2 (es)
CR (1) CR10852A (es)
DO (1) DOP2009000134A (es)
EA (1) EA015835B1 (es)
ES (1) ES2374952T3 (es)
IL (1) IL198922A0 (es)
MA (1) MA30983B1 (es)
MX (1) MX2009005935A (es)
MY (1) MY157365A (es)
NO (1) NO20092034L (es)
NZ (1) NZ577219A (es)
UA (1) UA97817C2 (es)
WO (1) WO2008070692A2 (es)
ZA (1) ZA200903952B (es)

Families Citing this family (96)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
RS20050532A (en) 2003-01-14 2007-12-31 Arena Pharmaceuticals Inc., 1,2,3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prpphylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia
US7501426B2 (en) 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
DOP2006000008A (es) * 2005-01-10 2006-08-31 Arena Pharm Inc Terapia combinada para el tratamiento de la diabetes y afecciones relacionadas y para el tratamiento de afecciones que mejoran mediante un incremento de la concentración sanguínea de glp-1
DE102005035891A1 (de) 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
PE20110235A1 (es) 2006-05-04 2011-04-14 Boehringer Ingelheim Int Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
CA2810522A1 (en) 2006-05-04 2007-11-15 Boehringer Ingelheim International Gmbh Polymorphs
US7638541B2 (en) 2006-12-28 2009-12-29 Metabolex Inc. 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine
CL2008000018A1 (es) * 2007-01-04 2008-08-01 Prosidion Ltd Compuestos derivados de heterociclos de nitrogeno y oxigeno, agonistas de gpcr; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de la obesidad, diabetes, sindrome metabolico, hiperlipidemia, toleranci
JP2010514832A (ja) * 2007-01-04 2010-05-06 プロシディオン・リミテッド ピペリジンｇｐｃｒアゴニスト
PE20081849A1 (es) * 2007-01-04 2009-01-26 Prosidion Ltd Derivados de piperidin-4-il-propoxi-benzamida como agonistas de gpcr
KR20100033419A (ko) 2007-07-19 2010-03-29 메타볼렉스, 인코포레이티드 당뇨병 및 대사 장애의 치료를 위한 ｒｕｐ3 또는 ｇｐｒ119 수용체의 작용제로서 ｎ-아자시클릭 치환된 피롤, 피라졸, 이미다졸, 트리아졸 및 테트라졸 유도체
WO2009106561A1 (en) * 2008-02-27 2009-09-03 Biovitrum Ab (Publ) Pyrazine compounds for treating gpr119 related disorders
PE20091730A1 (es) 2008-04-03 2009-12-10 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
EP2108960A1 (en) 2008-04-07 2009-10-14 Arena Pharmaceuticals, Inc. Methods of using A G protein-coupled receptor to identify peptide YY (PYY) secretagogues and compounds useful in the treatment of conditons modulated by PYY
KR20110026481A (ko) * 2008-06-20 2011-03-15 메타볼렉스, 인코포레이티드 아릴 ｇｐｒ１１９ 작동약 및 이의 용도
EP2324027B1 (en) * 2008-07-29 2016-02-24 Medichem, S.A. New crystalline salt forms of a 5,6,7,8-tetrahydro-1,2,4- triazolo[4,3-a]pyrazine derivative
EP2320910A4 (en) * 2008-07-30 2012-12-19 Glaxosmithkline Llc CHEMICAL COMPOUNDS AND ITS USE
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
KR20200118243A (ko) 2008-08-06 2020-10-14 베링거 인겔하임 인터내셔날 게엠베하 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
MX2011002558A (es) 2008-09-10 2011-04-26 Boehringer Ingelheim Int Terapia de combinacion para el tratamiento de diabetes y estados relacionados.
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
WO2010048149A2 (en) * 2008-10-20 2010-04-29 Kalypsys, Inc. Heterocyclic modulators of gpr119 for treatment of disease
BRPI0923121A2 (pt) 2008-12-23 2015-08-11 Boehringer Ingelheim Int Formas salinas de compostos orgânico
AR074990A1 (es) 2009-01-07 2011-03-02 Boehringer Ingelheim Int Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina
GB0904287D0 (en) * 2009-03-12 2009-04-22 Prosidion Ltd Compounds for the treatment of metabolic disorders
GB0904285D0 (en) * 2009-03-12 2009-04-22 Prosidion Ltd Compounds for the treatment of metabolic disorders
GB0904284D0 (en) * 2009-03-12 2009-04-22 Prosidion Ltd Compounds for the treatment of metabolic disorders
AR075988A1 (es) 2009-04-09 2011-05-11 Lilly Co Eli Compuesto de piridiloxi - pirrolidina inhibidor de recaptacion de serotonina y norepinefrina, composicion farmaceutica que lo comprende y su uso para la manufactura de un medicamento util para el tratamiento de dolor cronico
JP2012530758A (ja) 2009-06-24 2012-12-06 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規化合物、医薬組成物及びそれに関する方法
KR20120046188A (ko) 2009-06-24 2012-05-09 뉴로크린 바이오사이언시즈 인코퍼레이티드 신규 화합물, 약제학적 조성물 및 이에 관련된 방법
AR077642A1 (es) * 2009-07-09 2011-09-14 Arena Pharm Inc Moduladores del metabolismo y el tratamiento de trastornos relacionados con el mismo
WO2011030139A1 (en) * 2009-09-11 2011-03-17 Astrazeneca Ab 4- (pyrimidin-2-yl) -piperazine and 4- (pyrimidin-2-yl) -piperidine derivatives as gpr119 modulators
EP2483281B1 (en) 2009-10-01 2014-06-04 Cymabay Therapeutics, Inc. Substituted tetrazol-1-yl-phenoxymethyl-thiazol-2-yl-piperidinyl-pyrimidine salts
WO2011044001A1 (en) * 2009-10-09 2011-04-14 Irm Llc Compounds and compositions as modulators of gpr119 activity
KR102328772B1 (ko) 2009-11-27 2021-11-19 베링거 인겔하임 인터내셔날 게엠베하 리나글립틴과 같은 ｄｐｐ－ｉｖ 억제제를 사용한 유전자형 검사된 당뇨병 환자의 치료
US8853419B2 (en) 2010-01-27 2014-10-07 Arena Pharmaceuticals, Inc. Processes for the preparation of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid and salts thereof
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
US20130109703A1 (en) 2010-03-18 2013-05-02 Boehringer Ingelheim International Gmbh Combination of a GPR119 Agonist and the DPP-IV Inhibitor Linagliptin for Use in the Treatment of Diabetes and Related Conditions
US20130023494A1 (en) * 2010-04-06 2013-01-24 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
CA2797310C (en) 2010-05-05 2020-03-31 Boehringer Ingelheim International Gmbh Glp-1 receptor agonist and dpp-4 inhibitor combination therapy
TW201209054A (en) 2010-05-28 2012-03-01 Prosidion Ltd Novel compounds
WO2011150067A1 (en) * 2010-05-28 2011-12-01 Glaxosmithkline Llc Treatment of blood lipid abnormalities and other conditions
ITMI20100984A1 (it) * 2010-05-31 2011-12-01 Dipharma Francis Srl Procedimento per la preparazione di ossadiazoli
US8933024B2 (en) 2010-06-18 2015-01-13 Sanofi Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
BR112012032248A2 (pt) 2010-06-23 2016-09-13 Metabolex Inc composições de 5-etil-2-{4-[-4(-4-tetrazol-1-il-fenoximetil)-tiazol-2-il]-piperidin-1-il}-pirimidina
EA201991014A1 (ru) 2010-06-24 2019-09-30 Бёрингер Ингельхайм Интернациональ Гмбх Лечение диабета
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
WO2012025811A1 (en) 2010-08-23 2012-03-01 Lupin Limited Indolylpyrimidines as modulators of gpr119
MX2013003184A (es) 2010-09-22 2013-06-07 Arena Pharm Inc Moduladores del receptor gpr119 y el tratamiento de transtornos relacionados con el mismo.
JP5873877B2 (ja) * 2010-10-11 2016-03-01 セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー セロトニン再取込みインヒビター
AR083878A1 (es) 2010-11-15 2013-03-27 Boehringer Ingelheim Int Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
CA2818050A1 (en) 2010-11-26 2012-05-31 Lupin Limited Bicyclic gpr119 modulators
UY33805A (es) * 2010-12-17 2012-07-31 Boehringer Ingelheim Int ?Derivados de dihidrobenzofuranil-piperidinilo, aza-dihidrobenzofuranilpiperidinilo y diaza-dihidrobenzofuranil-piperidinilo, composiciones farmacéuticas que los contienen y usos de los mismos?.
LT3002278T (lt) 2011-03-15 2017-06-26 Astellas Pharma Inc. Guanidino junginys
CN102731492B (zh) * 2011-03-30 2016-06-29 江苏恒瑞医药股份有限公司 环己烷类衍生物、其制备方法及其在医药上的应用
US20140018371A1 (en) * 2011-04-01 2014-01-16 Arena Pharmaceuticals, Inc. Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
WO2012138845A1 (en) * 2011-04-08 2012-10-11 Merck Sharp & Dohme Corp. Substituted cyclopropyl compounds, compositions containing such compounds and methods of treatment
KR20190062621A (ko) 2011-07-15 2019-06-05 베링거 인겔하임 인터내셔날 게엠베하 치환된 퀴나졸린, 이의 제조 및 약제학적 조성물에서의 이의 용도
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
US8853239B2 (en) * 2011-12-09 2014-10-07 Boehringer Ingelheim International Gmbh Compounds, pharmaceutical compositions and uses thereof
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
MX355129B (es) * 2012-03-22 2018-04-06 Millendo Therapeutics Inc Compuestos y metodos para el tratamiento de trastornos celulares adrenocorticales aberrantes.
EP3685839A1 (en) 2012-05-14 2020-07-29 Boehringer Ingelheim International GmbH Linagliptin for use in the treatment of albuminuria and kidney related diseases
US20130303554A1 (en) 2012-05-14 2013-11-14 Boehringer Ingelheim International Gmbh Use of a dpp-4 inhibitor in sirs and/or sepsis
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
PT2858986T (pt) * 2012-06-12 2019-11-29 Chong Kun Dang Pharmaceutical Corp Derivados de piperidina como agonistas de gpr119
CA2930850C (en) * 2013-11-26 2017-05-16 Chong Kun Dang Pharmaceutical Corp. Amide derivatives for gpr119 agonist
WO2015128453A1 (en) 2014-02-28 2015-09-03 Boehringer Ingelheim International Gmbh Medical use of a dpp-4 inhibitor
KR101651505B1 (ko) * 2014-05-02 2016-08-29 현대약품 주식회사 싸이클로 헥센 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 대사성 질환의 예방 또는 치료용 약학적 조성물
WO2015167309A1 (ko) * 2014-05-02 2015-11-05 현대약품 주식회사 싸이클로 헥센 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 대사성 질환의 예방 또는 치료용 약학적 조성물
EP4445956A3 (en) 2015-01-06 2024-12-04 Arena Pharmaceuticals, Inc. Compound for use in treating conditions related to the s1p1 receptor
CN104610393A (zh) * 2015-02-13 2015-05-13 佛山市赛维斯医药科技有限公司 一类含氨基葡萄糖和卤代吡啶结构化合物及其用途
CN104610390A (zh) * 2015-02-13 2015-05-13 佛山市赛维斯医药科技有限公司 一种含氨基葡萄糖和腈基吡啶结构的gpr119激动剂及其用途
HUE060476T2 (hu) 2015-06-22 2023-03-28 Arena Pharm Inc (R)-2-(7-(4-ciklopentil-3-(trifluormetil)benziloxi)-1,2,3,4- tetrahidrociklopenta[B]indol-3-il)ecetsav kristályos L-arginin-sója S1P1 receptorral kapcsolatos rendellenességek esetén való alkalmazásra
EP3352750A1 (en) * 2015-11-04 2018-08-01 Hyundai Pharm Co., Ltd. Cyclohexene derivative, preparation method thereof, and pharmaceutical composition for preventing or treating metabolic disease comprising the same as active ingredient
WO2017123991A1 (en) * 2016-01-15 2017-07-20 The Brigham And Women's Hospital, Inc. Pyridazine derivatives as eaat2 activators
EP4233840A3 (en) 2016-06-10 2023-10-18 Boehringer Ingelheim International GmbH Combinations of linagliptin and metformin
JP2019527693A (ja) 2016-08-03 2019-10-03 サイマベイ・セラピューティクス・インコーポレイテッドＣｙｍａＢａｙ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． 炎症性胃腸疾患または胃腸状態を治療するためのオキシメチレンアリール化合物
CA3053418A1 (en) 2017-02-16 2018-08-23 Arena Pharmaceuticals, Inc. Compounds and methods for treatment of primary biliary cholangitis
WO2018160024A1 (ko) * 2017-02-28 2018-09-07 한국화학연구원 피페리딘-아릴 유도체 또는 이의 약학적으로 허용 가능한 염, 이의 제조방법, 및 이를 유효성분으로 함유하는 약제학적 조성물
CN112601516A (zh) 2018-06-06 2021-04-02 艾尼纳制药公司 治疗与s1p1受体相关的病况的方法
JOP20210157A1 (ar) 2018-12-21 2023-01-30 Ogeda Sa تخليق 3-ميثيل-1، 2، 4-ثياديازول-5-كربوهيدرازيد أو ميثيل-d3 مُعَالَج بالديوتيريوم منه
GB201905520D0 (en) 2019-04-18 2019-06-05 Modern Biosciences Ltd Compounds and their therapeutic use
CN110514759B (zh) * 2019-08-21 2022-05-20 天地恒一制药股份有限公司 一种坎地沙坦酯中叠氮化合物的检测方法
EP4110788A4 (en) 2020-02-28 2024-08-28 Kallyope, Inc. Gpr40 agonists
JP2023526625A (ja) 2020-05-19 2023-06-22 キャリーオペ，インク． Ａｍｐｋアクチベーター
JP2023531726A (ja) 2020-06-26 2023-07-25 キャリーオペ，インク． Ａｍｐｋアクチベーター
CN113527152B (zh) * 2021-08-09 2023-07-28 西北农林科技大学 一种联苯磺酰胺类化合物及其防治农作物害虫的方法
IL291418B2 (en) 2022-03-16 2024-05-01 Anima Biotech Inc C-myc mrna translation modulators and uses thereof in the treatment of cancer

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE15667T1 (de) 1980-06-27 1985-10-15 Beiersdorf Ag Neue substituierte 3,5-diamino-1,2,4-oxadiazole und 3,5-diamino-1,2,4-thiadiazole, verfahren zu ihrer herstellung und sie enthaltende pharmazeutische praeparate.
US5231184A (en) 1987-11-23 1993-07-27 Janssen Pharmaceutica N.V. Pridazinamine derivatives
US5109002A (en) * 1989-09-08 1992-04-28 Du Pont Merck Pharmaceutical Company Antipsychotic 1-cycloalkylpiperidines
AU1698997A (en) 1996-01-16 1997-08-11 Merck & Co., Inc. Tocolytic oxytocin receptor antagonists
JP3055135B2 (ja) 1996-12-26 2000-06-26 田辺製薬株式会社 プロピオフェノン誘導体及びその製法
TR200201082T2 (tr) 1999-08-31 2002-07-22 Kissei Pharmaceutical Co., Ltd. Glikopriranoziloksipirazol türevleri
US20020151712A1 (en) 1999-09-14 2002-10-17 Nan-Horng Lin 3-pyrrolidinyloxy-3'-pyridyl ether compounds useful for controlling chemical synaptic transmission
US6515117B2 (en) 1999-10-12 2003-02-04 Bristol-Myers Squibb Company C-aryl glucoside SGLT2 inhibitors and method
PH12000002657B1 (en) 1999-10-12 2006-02-21 Bristol Myers Squibb Co C-aryl glucoside SGLT2 inhibitors
JP4456768B2 (ja) 2000-02-02 2010-04-28 壽製薬株式会社 Ｃ−配糖体を含有する薬剤
CN1177857C (zh) 2000-03-17 2004-12-01 橘生药品工业株式会社 吡喃葡萄糖氧基苄基苯衍生物、包含该物质的药用组合物及制备该衍生物用的中间体
US6683056B2 (en) 2000-03-30 2004-01-27 Bristol-Myers Squibb Company O-aryl glucoside SGLT2 inhibitors and method
US6555519B2 (en) 2000-03-30 2003-04-29 Bristol-Myers Squibb Company O-glucosylated benzamide SGLT2 inhibitors and method
DK1329456T3 (da) 2000-09-29 2006-12-04 Kissei Pharmaceutical Glucopyranosyloxybenzylbenzenderivater og medicinske sammensætninger indeholdende samme
ATE455785T1 (de) 2000-11-02 2010-02-15 Ajinomoto Kk Neue pyrazolderivate und diese enthaltende mittel gegen diabetes
CA2429833A1 (en) 2000-11-30 2002-06-06 Kissei Pharmaceutical Co., Ltd. Glucopyranosyloxybenzylbenzene derivatives, medicinal compositions containing the same and intermediates in the production thereof
CN1482912A (zh) * 2000-12-21 2004-03-17 ���鹫˾ 杂芳基脲神经肽yy5受体拮抗剂
CZ305971B6 (cs) 2000-12-28 2016-06-01 Kissei Pharmaceutical Co., Ltd. Deriváty glukopyranosyloxypyrazolu a jejich použití v léčivech
EP1480957A1 (en) 2002-03-01 2004-12-01 Smithkline Beecham Corporation Hppars activators
US6995144B2 (en) 2002-03-14 2006-02-07 Eisai Co., Ltd. Nitrogen containing heterocyclic compounds and medicines containing the same
RS20050532A (en) 2003-01-14 2007-12-31 Arena Pharmaceuticals Inc., 1,2,3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prpphylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia
FR2865205B1 (fr) * 2004-01-16 2006-02-24 Sanofi Synthelabo Derives de type aryloxyalkylcarbamates, leur preparation et leur application en therapeutique
BRPI0511757A (pt) 2004-06-04 2008-01-08 Arena Pharm Inc derivados de arila e heteroarila substituìdos como moduladores de metabolismo e a profilaxia e tratamento de distúrbios relacionados a este
AR053712A1 (es) * 2005-04-18 2007-05-16 Neurogen Corp Heteroarilos sustituidos, antagonistas de cb1 (receptor 1 canabinoide)
GB0510139D0 (en) 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds B1
KR20080027908A (ko) 2005-06-30 2008-03-28 프로시디온 리미티드 Ｇｐｃｒ 효능제
TW200806292A (en) 2006-01-25 2008-02-01 Synta Pharmaceuticals Corp Vinyl-phenyl derivatives for inflammation and immune-related uses
JP2010501630A (ja) * 2006-08-30 2010-01-21 ビオヴィトルム・アクチボラゲット（プブリクト） Ｇｐｒ１１９関連障害を治療するためのピリミジン化合物

Also Published As

Publication number Publication date
CN101657471A (zh) 2010-02-24
NO20092034L (no) 2009-06-30
KR20090097184A (ko) 2009-09-15
JP5330260B2 (ja) 2013-10-30
EA200900623A1 (ru) 2009-12-30
AU2007329395A1 (en) 2008-06-12
DOP2009000134A (es) 2009-10-15
CR10852A (es) 2009-08-12
HK1130261A1 (en) 2009-12-24
UA97817C2 (ru) 2012-03-26
BRPI0719941A2 (pt) 2014-04-22
US20100029650A1 (en) 2010-02-04
CA2671749C (en) 2013-07-09
MY157365A (en) 2016-05-31
JP2010512334A (ja) 2010-04-22
CO6210752A2 (es) 2010-10-20
NZ577219A (en) 2011-11-25
WO2008070692A3 (en) 2008-08-21
US20120077812A1 (en) 2012-03-29
ES2374952T3 (es) 2012-02-23
EP2094683B1 (en) 2011-10-12
IL198922A0 (en) 2010-02-17
AU2007329395B2 (en) 2012-05-31
EP2094683A2 (en) 2009-09-02
EA015835B1 (ru) 2011-12-30
WO2008070692A2 (en) 2008-06-12
EP2325182A1 (en) 2011-05-25
MA30983B1 (fr) 2009-12-01
CA2671749A1 (en) 2008-06-12
WO2008070692A8 (en) 2008-12-24
CN101657471B (zh) 2013-07-03
ZA200903952B (en) 2010-11-24
US8101634B2 (en) 2012-01-24
ATE528300T1 (de) 2011-10-15

Similar Documents

Publication Publication Date Title
MX2009005935A (es) Compuestos biciclicos y su uso como anti-diabeticos.
WO2008008887A3 (en) Gpr119 agonists for treating metabolic disorders
TW200608961A (en) Methods and reagents for the treatment of metabolic disorders
MX2007010560A (es) Roflumilast para el tratamiento de diabetes mellitus.
TW200637845A (en) Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto
TW200637844A (en) Processes for preparing aromatic ethers
WO2010029089A3 (en) Combination therapy for the treatment of diabetes and related conditions
AU2007221366A8 (en) Oxyntomodulin derivatives
WO2007127505A3 (en) Use of sulfonamide derivatives in the treatment of disorders of the metabolism and the nervous system
MX2009004108A (es) Compuestos de tetrahidropirrolopiracina sustituidos teniendo afinidad al canal kcnq2/3 k+ y su uso en farmacos.
MY157911A (en) Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto
TW200700064A (en) Novel compounds
PH12016501607B1 (en) Sglt-2 inhibitor for treating type 1 diabetes mellitus, type 2 diabetes mellitus, impaired glucose tolerance or hyperglycemia
PL1891004T3 (pl) Pentafluorosulfanylo-podstawiony związek i jego zastosowanie do wytwarzania środków leczniczych
WO2007115821A3 (en) Organic compounds
WO2009077471A3 (de) Azolylmethyloxirane, ihre verwendung sowie sie enthaltende mittel
WO2007122382A3 (en) Lycopene for the treatment of metabolic dysfunction
PL1779858T3 (pl) Zastosowanie związków selenu, w szczególności drożdży selenowych, do zmieniania funkcji poznawczych
EA201201623A1 (ru) Лечение диабета 2 типа
MX2009004983A (es) Pirazoles sustituidos, composiciones que los contienen, procedimiento de fabricacion y utilizacion.
UA101297C2 (ru) Замещенное циклическое соединение, способ его получения и его медицинское применение
WO2007009704A3 (en) Use of substituted pyrazoline compounds for the treatment of food disorders, including obesity or metabolic syndrome in patients with developed diabetes
IL200192A0 (en) Composition useful for the treatment of type 2 diabetes
WO2008008507A3 (en) Methods of treatment of diabetes
WO2009005469A3 (en) The use of compounds such as pyridoxal derivatives for the treatment of diabetes or diseases associated with the metabolic syndrome

Legal Events

Date Code Title Description
FG Grant or registration